|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:imiglucerase
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:alternativeTo
|
gptkb:Cerdelga
gptkb:Elelyso
gptkb:VPRIV
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
A16AB03
|
|
gptkbp:contraindication
|
hypersensitivity to imiglucerase
|
|
gptkbp:cost
|
high
|
|
gptkbp:form
|
lyophilized powder for solution
|
|
gptkbp:halfLife
|
3.6-10.4 minutes
|
|
gptkbp:indication
|
long-term enzyme replacement therapy
treatment of chronic neuronopathic Gaucher disease
treatment of non-neuronopathic Gaucher disease
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
gptkb:enzyme_replacement_therapy
|
|
gptkbp:orphanDrugStatus
|
yes
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:product
|
recombinant human beta-glucocerebrosidase
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
fatigue
headache
pruritus
rash
infusion reaction
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:usedFor
|
gptkb:Gaucher_disease_type_1
gptkb:Gaucher_disease_type_3
|
|
gptkbp:bfsParent
|
gptkb:Genzyme
gptkb:Genzyme_(2011)
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cerezyme
|